首页|20(S)-Ginsenoside Rh2 inhibits hepatocellular carcinoma by suppressing angiogenesis and the GPC3-mediated Wnt/β-catenin signaling pathway
20(S)-Ginsenoside Rh2 inhibits hepatocellular carcinoma by suppressing angiogenesis and the GPC3-mediated Wnt/β-catenin signaling pathway
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
万方数据
20(S)-Ginsenoside Rh2 has significant anti-tumor effects in various types of cancers,including human hepatocel-lular carcinoma(HCC).However,its molecular targets and mechanisms of action remain largely unknown.Here,we aim to elucidate the potential mechanisms by which Rh2 suppresses HCC growth.We first demonstrate the role of Rh2 in inhibiting angiogenesis.We observe that Rh2 effectively suppresses cell proliferation and induces apoptosis in HUVECs.Furthermore,Rh2 significantly inhibits HepG2-stimulated HUVEC proliferation,migration and tube formation,accompanied by the downregulation of VEGF and MMP-2 expressions.We also reveal that Rh2 inhibits HCC growth through the down regulation of glypican-3-mediated activation of the Wnt/β-catenin pathway.We observe a dose-dependent inhibition of proliferation and induction of apoptosis in HepG2 cells upon Rh2 treatment,which is mediated by the inhibition of glypican-3/Wnt/β-catenin signaling.Moreover,downregulation of glypican-3 expression enhances the effects of Rh2 on the glypican-3/Wnt/β-catenin signaling pathway,resulting in greater suppression of tumor growth in HepG2 cells.Collectively,our findings shed light on the molecular mechanisms through which Rh2 modulates HCC growth,which involve the regulation of angiogenesis and the glypican-3/Wnt/β-catenin pathway.These insights may pave the way for the development of novel therapeutic strategies targeting these pathways for the treatment of HCC.
NETL
NSTL
万方数据
